Sunday, October 30, 2016 9:53:50 PM
The potential is so obvious. $5.7 with only 4 countries online and with a small initial group of patients receiving the implant in those countries. If we reach 20 European countries and get to treat the patients who are standing in line to receive Scenesse at this moment, then we could easily see $100 m per year in Europe for EPP alone. Add the almost certain FDA approval and we could arrive at $150 m per year. Add partnership for Vitiligo, subsequent FDA approval and label extensions within 3-5 years and the sky is the limit. Event the risk weighted valuation of Vitiligo once a partner is on board could be substantial. Clinuvel is in track to become a +$50 stock within few months / years.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM